aflibercept-abzv (Enzeevu) vs BAT5906
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
aflibercept-abzv (Enzeevu)
Marketed by Sandoz Group AG
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
BAT5906
Developed by Bio-Thera Solutions
NCT05439629 · Phase 3 · completed
The study randomized 488 participants to BAT5906 or active treatment with Lucentis and masked participants, care providers, and investigators. Its primary outcomes were clinical measures of visual acuity, but the registry does not report whether the comparison was favorable or statistically significant, so the evidence remains limited pending results.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
aflibercept-abzv (Enzeevu): registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.
BAT5906: no structured comparison results are available for Age-Related Macular Degeneration.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-abzv (Enzeevu)'s landscape · BAT5906's landscape